David Liberg - Cantargia Vice President Cancer Research
| CANTA Stock | SEK 1.83 0.01 0.55% |
President
Mr. David Liberg was appointed Vice President Cancer Research at Cantargia AB effective as of December 1, 2015. Liberg has nearly twenty years of research experience within immunology and tumor biology and was graduated with a Doctorate in Philosophy in immunology in 2001. Liberg has for the last ten years worked within the pharmaceutical industry, with responsibility for early research projects and activities in tumor immunology. Liberg has extensive experience of leading cancer projects in preclinical phases and his latest position was at Active Biotech AB as Project Manager Drug Development as well as head of Cell Biology and Biochemistry. Liberg has also worked with science at Imperial College in UK and at Lund University. since 2015.
| Age | 46 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 46 4 62 75 62 60 |
| Web | https://www.cantargia.com |
Cantargia Management Efficiency
The company has return on total asset (ROA) of (0.3963) % which means that it has lost $0.3963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6913) %, meaning that it generated substantial loss on money invested by shareholders. Cantargia's management efficiency ratios could be used to measure how well Cantargia manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Christian Kjellman | Hansa Biopharma AB | 56 | |
| Henk Troostwijk | Hansa Biopharma AB | 58 | |
| Peter Ellmark | Alligator Bioscience AB | 50 | |
| EvaMaria Joed | Hansa Biopharma AB | 54 | |
| Lena Winstedt | Hansa Biopharma AB | 54 | |
Management Performance
| Return On Equity | -0.69 | |||
| Return On Asset | -0.4 |
Cantargia AB Leadership Team
Elected by the shareholders, the Cantargia's board of directors comprises two types of representatives: Cantargia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cantargia. The board's role is to monitor Cantargia's management team and ensure that shareholders' interests are well served. Cantargia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cantargia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karin Leandersson, Director | ||
| Magnus Persson, Chairman of the Board | ||
| Dominique Tersago, Chief Officer | ||
| Liselotte Larsson, Vice President - Operations | ||
| David Liberg, Vice President Cancer Research | ||
| Kjell Sjstrm, Founder | ||
| Johanna Christensen, Financial Controller | ||
| Goran Forsberg, Chief Executive Officer | ||
| Nina Valkama, Exec Fin | ||
| Bengt Jondell, Chief Financial Officer | ||
| Adnan Deronic, IP Mang | ||
| Lars Thorsson, Vice President Clinical Development | ||
| Ignacio GarciaRibas, Chief Medical Officer | ||
| Susanne Lagerlund, Vice President - Regulatory Affairs | ||
| Thoas MD, Founder Director | ||
| Marcuss, Founder Advisor | ||
| Anders MartinLof, Director | ||
| Thoas Fioretos, Director | ||
| Patricia Delaite, Director | ||
| Claus Andersson, Director | ||
| Peter Madsen, Vice President - CMC |
Cantargia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cantargia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.69 | |||
| Return On Asset | -0.4 | |||
| Current Valuation | 34.5 M | |||
| Shares Outstanding | 166.99 M | |||
| Shares Owned By Insiders | 9.10 % | |||
| Shares Owned By Institutions | 33.60 % | |||
| Price To Earning | 2.12 X | |||
| Price To Book | 1.11 X | |||
| EBITDA | (363.06 M) | |||
| Net Income | (370.27 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cantargia Stock Analysis
When running Cantargia's price analysis, check to measure Cantargia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cantargia is operating at the current time. Most of Cantargia's value examination focuses on studying past and present price action to predict the probability of Cantargia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cantargia's price. Additionally, you may evaluate how the addition of Cantargia to your portfolios can decrease your overall portfolio volatility.